Sudocetaxel zendusortide
Peptideexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 4, 2021 (NCT04706962)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Genital Neoplasms, Female · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Thyroid Neoplasms · Phase 1
Mechanism of action
- Neurotensin receptor 3INHIBITOR
SORT1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095153 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04706962 | Phase 1 | Mar 4, 2021 | PPD, Theratechnologies, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PPD | For profit | 1 | 0 | 1 | 2021 |
| Theratechnologies | For profit | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1